Novavax to File Vaccine in U.K. and U.S. in Q2, CEO Says

The transcript discusses the process of filing vaccine data in the UK and US, highlighting the efficacy of the vaccine against severe cases and variants. It covers the adaptation of vaccines for booster shots, addressing vaccine nationalism, and the global manufacturing strategy. Safety concerns are also discussed, along with the timeline for future booster shots.

What is the UK equivalent of the FDA mentioned in the filing process?

• EMA

• WHO

• MHRA

• CDC

What protein is used by all vaccine makers to stimulate an immune response?

• Envelope protein

• Spike protein

• Membrane protein

• Nucleocapsid protein

What is the efficacy percentage of the vaccine against severe disease, even among some variants?

• 75%

• 85%

• 95%

• 100%

What was the efficacy of the vaccine in South Africa against the variant?

• 55%

• 45%

• 65%

• 75%

What is the term used to describe the phenomenon where prior infections provide some protection against new variants?

• Herd immunity

• Viral resistance

• Cross-immunity

• Antigenic shift

What strategy has been adopted to address vaccine nationalism?

• Exclusive US production

• Global manufacturing supply chain

• EU-focused distribution

• Centralized manufacturing

What is a key concern for vaccine manufacturers when developing vaccines?

• Safety

• Speed of production

• Cost-effectiveness

• Market demand